Publications & Reports

Improving hepatitis C direct-acting antiviral access and uptake: a role for patient-reported outcomes and lived-experience.

Goutzamanis S, Doyle J, Higgs P, Hellard M
Disease Elimination Program, Burnet Institute.

Abstract

With approximately 71 million people chronically infected worldwide and 1.75 million new infections in 2015, hepatitis C virus remains a significant public health concern. In developed countries hepatitis C transmission is predominantly driven by the sharing of injecting equipment, placing people who inject drugs (PWID) at the greatest risk of infection. It is estimated that approximately half of the PWID population are hepatitis C antibody positive. This article is protected by copyright. All rights reserved.

Link to publisher’s web site